Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2832883 | 0.99 | CASP3 (0.42) | CASP3MEN1KMT2APLA2G2AEGLN2 | |
| SCHEMBL454479 | 0.94 | MEN1 (0.41) | CASP3MEN1KMT2APLA2G2AEGLN2 | |
| Hydrochloric Acid SCHEMBL2831200 | 0.94 | MEN1 (0.41) | CASP3MEN1KMT2APLA2G2AEGLN2 | |
| SCHEMBL4718028 | 0.87 | EGLN2 (0.42) | MEN1KMT2AEGLN2EGLN1BBOX1 | |
| SCHEMBL456583 | 0.86 | GAA (0.39) | MEN1KMT2AGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2834084 | 0.85 | GAA (0.39) | MEN1KMT2AGAAPPARGNPC1 | |
| SCHEMBL2829605 | 0.85 | MEN1 (0.44) | MEN1KMT2APLA2G2AEGLN2EGLN1 | |
| Succinic Acid SCHEMBL13739526 | 0.85 | FFAR1 (0.40) | MEN1KMT2APLA2G2AEGLN2EGLN1 | |
| Acetic Acid SCHEMBL20422024 | 0.85 | MEN1 (0.41) | MEN1KMT2APLA2G2ACHEK2PPARG | |
| Hydrochloric Acid SCHEMBL2830133 | 0.84 | MEN1 (0.43) | MEN1KMT2AEGLN2EGLN1BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-09-14 | — | — | US | claimed |
| US-9694006-B2 | Use of pyrroloquinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-07-04 | — | — | US | claimed |
| US-20130096151-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2013-04-18 | — | — | US | claimed |
| EP-2552440-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2013-02-06 | — | — | EP | claimed |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2012-09-13 | — | — | US | claimed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | claimed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| EP-3228314-B1 | SULOCTIDIL FOR USE TO TREAT MICROBIAL INFECTIONS | HELPERBY THERAPEUTICS LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10265373-B2 | Pharmaceutical composition and method of treating a microbial infection with sulcotidil | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| WO-2018162928-A1 | METHOD FOR RESTORING EFFICACY OF AN ANTIBACTERIAL AGENT | HELPERBY THERAPEUTICS LIMITED (GB) | 2018-09-13 | — | — | WO | disclosed |
| US-9789101-B2 | Methods and compositions for treating microbial infection using pyrroloquinone | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3228314-A1 | VASODILATOR FOR USE TO TREAT MICROBIAL INFECTIONS | Helperby Therapeutics Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1945211-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054693-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258784-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | CASP3 48/4885MEN1 1394/4885KMT2A 2403/4885 |
| US-20130096151-A1 | NOVEL COMBINATION AND USE | FPR2, LTA, FPR1 | CASP3 201/4885MEN1 4865/4885KMT2A 2810/4885 |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | CASP3 48/4885MEN1 1394/4885KMT2A 2403/4885 |
| US-20120231995-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | CASP3 48/4885MEN1 1394/4885KMT2A 2403/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | CASP3 1100/4885MEN1 2763/4885KMT2A 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.